Skip to main content

Table 1 Baseline characteristics

From: Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

Median age, years (range)

73 (33–91)

WHO diagnosis*, n (%)

 

 t-AML

16 (10.3)

 AML-RCA

16 (10.3)

 AML-MRF only

88 (56.8)

   AML-MRC

13 (8.4)

   Preexisting MDS/MPN or MLD

58 (37.4)

   Preexisting MDS/MPN or MLD + MRC

17 (11.0)

   AML-NOS

35 (22.6)

Peripheral blood blasts, n (%)

 

 0%

58 (37.4)

 > 0%

97 (62.6)

 Mean,%

14

 Median (range),%

3 (0–90)

Bone marrow blasts, n (%)

 

 <20%†

26 (16.8)

 20–30%

31 (20.0)

 >30% (off label use)

98 (63.2)

 Mean,%

42

 Median (range),%

35 (0–98)

White blood cell count, n (%)

 

 Non-MP-AML (< 10 G/l)

122 (78.7)

 MP-AML (> 10 G/l)

33 (21.3)

Transfusion dependence (TD), n (%)

 

 Any type of TD

101 (65.2)

 RBC-TD

97 (62.6)

 PLT-TD

60 (38.7)

 RBC-TD + PLT-TD

56 (36.1)

IPSS cytogenetic risk‡, n (%)

 

 Not evaluable

11 (7.1)

 Good

91 (58.7)

 Intermediate

26 (16.1)

 Poor

27 (17.4)

MRC cytogenetic risk‡, n (%)

 

 Not evaluable

11 (7.1)

 Good

3 (1.9)

 Intermediate

115 (74.2)

 High

26 (16.8)

Comorbidities, n (%)

 

 Thromboembolic episodes

21 (13.5)

 Renal insufficiency

29 (18.7)

 Liver disease

20 (12.9)

 Diabetes mellitus

26 (16.8)

 Coronary artery disease

34 (21.9)

 COPD

15 (9.7)

 Prior/concomitant malignancies

35 (22.6)

Number of comorbidities, n (%)

 

 0–1

66 (42.6)

 2–3

61 (39.4)

 > 3

28 (18.1)

ECOG Prognostic Score, n (%)

 

 ECOG <2

114 (73.6)

 ECOG ≥2

41 (26.4)

HCT-CI, n (%)

 

 Low risk

46 (29.7)

 Int. risk

46 (29.7)

 High risk

50 (32.2)

 No data

13 (8.4)

Treatment prior to azacitidine§, n (%)

 

 None

63 (40.6)

 Erythropoietin stimulating agents

15 (9.7)

 G-CSF

19 (12.3)

 Thrombopoietin stimulating agents

1 (0.7)

 Iron chelation therapy

5 (3.2)

 Thalidomide

3 (1.9)

 Lenalidomide

6 (3.9)

 Low-dose cytarabine

10 (6.5)

 Intensive chemotherapy

60 (38.7)

 Others

16 (10.3)

Reason for treatment, n (%)

 

 1st line treatment

63 (40.6)

 Bridging to allogeneic SCT#

4 (2.6)

 Maintenance after CR to conventional chemotherapy

6 (3.9)

 No CR to/early relapse after conventional chemotherapy

45 (29.0)

 No CR to/early relapse after allogeneic SCT

5 (3.2)

 No CR to other prior treatment

32 (20.6)

  1. t-AML indicates treatment related AML; AML-RCA, AML with recurrent cytogenetic abnormalities; AML-MRF, AML with MDS related features; MPN, myeloproliferative neoplasia; MLD, multilineage dysplasia; MRC, MDS-related cytogenetics; AML-NOS, AML not otherwise specified; MP, myeloproliferative; COPD, chronic obstructive pulmonary disease; NHL, non-Hodgkin’s lymphoma; ECOG, Eastern Cooperative Oncology Group; CR, complete response; SCT, stem cell transplantation;
  2. *If a patient fulfilled criteria for more than one WHO-category, weighting was performed as follows: t-AML > AML-RCA > AML-MRF.
  3. †BM-blast count was <20%, in those patients with established AML who were refractory to, -or had no CR after-, conventional chemotherapy or allogeneic stem cell transplantation.
  4. ‡Pre-treatment cytogenetics were available in 92% of patients and were determined by conventional metaphase karyotyping (46%), interphase-FISH (16%), or both (38%).
  5. §Numbers may add up to >100% as multiple selections were possible.
  6. #None of the patients for whom azacitidine was intended as bridging was in complete remission to prior therapies, and all patients had relapsed after multiple lines of intensive chemotherapy; only one of these patients proceeded to allogeneic SCT (the others died whilst still on, or within 8 weeks after termination of azacitidine treatment due to disease progression and/or infectious complications).
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us